[
  {
    "ts": null,
    "headline": "Why Gilead Sciences Remains A Buy After A 40% Rally",
    "summary": "Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term investors. See more on GILD stock here.",
    "url": "https://finnhub.io/api/news?id=1582af67631cc15c84ec098d47f1c3e9752315ef00f6ae8ee73a59d809bc89ef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740610521,
      "headline": "Why Gilead Sciences Remains A Buy After A 40% Rally",
      "id": 132896295,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/492146371/image_492146371.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term investors. See more on GILD stock here.",
      "url": "https://finnhub.io/api/news?id=1582af67631cc15c84ec098d47f1c3e9752315ef00f6ae8ee73a59d809bc89ef"
    }
  }
]